显示标签为“recombinant LARGE”的博文。显示所有博文
显示标签为“recombinant LARGE”的博文。显示所有博文

2016年11月8日星期二

External environment and oxidation threats DNA most

Recently a study has found that forces from external environment and oxidation may be the greatest threat to an organism's ability to repair damage to its own DNA. The results are published in the journal of the Proceedings of the National Academy of Sciences, which also publishes some other studies on Recombinant protein. The results are based on the first comprehensive, whole genome analysis of spontaneous mutation in the bacterium Escherichia coli.

"Our study investigated 11 DNA repair pathways previously identified as resulting in spontaneous mutations," said Foster, a professor in the IU Bloomington College of Arts and Sciences' Department of Biology. "The striking result was that only loss of the ability to prevent or repair oxidative DNA damage significantly impacted mutation rates. ... All other forms of DNA damage arising within the organism did not disturb the overall accuracy of DNA replication in normally growing cells.

"These results suggest that DNA repair pathways may exist primarily to defend against externally induced damage to the genome," she said. Foster's lab and her work concentrates on DNA mutagenesis and repair. E. coli is a bacterium discovered in mammalian digestive tracts. It's more known as a source of food poisoning. It was chosen for the research because the biological pathways that control DNA repair have changed little as more complex organisms evolved, increasing the chances that the study's results are applicable to higher forms of life, including humans.

Foster's lab created the world's most comprehensive picture of genetic mutation in the species by tracing changes in E. coli's complete genome over the course of 200,000 generations. The IU team concentrated on 11 processes identified in other studies as causing mutation when deactivated, to focus their investigation on the relative importance of the pathways that repair DNA damage to genetic mutation. The pathways were isolated using 11 different strains of E. coli, each defective for one of the specific pathways.

After investigation, the DNA repair pathways under investigation fell into three broad categories. They were the activities of error-prone DNA polymerases, repair of internally induced DNA damage, including oxidation, and repair of DNA damage due to external agents. Each pathway is more or less specific for a given type of DNA damage. External agents such as radiation, chemical compounds and platinum-based compounds, are forces that affect DNA. And internal agents that damage DNA are produced by the body's own normal processes. Oxidation occurs in the body as a result of metabolic processes that use oxygen, creating molecules known as "free radicals" that steal electrons from other molecules in the body, causing damage. Many types of cancer and even aging have been linked to DNA oxidation.

The IU scientists used whole genome sequencing to catalog the specific genetic changes that resulted from loss of each repair pathway. Foster said that, surprisingly, the IU team found that none of the pathways resulted in mutations except the ones that deal with damage from oxidation. This means that the other types of damage—from either internal or external causes—are not a great threat to normally growing cells.

These pathways may be important, however, when cells are exposed to external agents or other forms of stress. The more complete picture of genetic mutation—made possible by the IU team's previous documentation of the bacterium's evolution over 200,000 generations—is likely responsible for the difference in the study's results compared to previous research implicating all 11 DNA repair pathways in genetic mutation, Foster said.

"Previous studies on mutational processes have relied on reporter genes"—single genes that signal larger changes across the genome—"to detect mutations, and these may not be representative of the genome as a whole," she said. "While reporter genes can reveal important mutational processes that occur at particular spots in the DNA, when the whole genome is the target, these localized errors don't appear to contribute to overall mutation."

Foster's next step is investigate DNA repair functions in cells under stress, which may provide a more complete model for mutational processes in living human cells existing in different states and environments all over the body. The experiments and research can help scientists understand more about DNA repair in our body and the importance of them. Flarebio offers good-quality recombinant proteins like recombinant LARGE at good prices.

2016年11月7日星期一

The risk of cancer can be reduced by gene therapy

Scientists at Washington State University have developed a gene therapy that is expected to reduce the spread of cancer cells. According to the report of International community, gene therapy is a kind of experimental medical technology for the treatment of a variety of genetic diseases. In many experiments, new genes are implanted in the body to help the body fight the disease to replace the damaged genes. According to a study published in the journal Scientific Reports which also publishes other studies on recombinant horse proteins, researchers at Washington State University have changed the way that viruses carry beneficial genes into target cells, thus reducing the risk of cancer-induced blood diseases.

The lead investigator of this study Grant Trobridge and his team are also developing treatments that use stem cells to treat neonatal immunodeficiency, also known as the Boys Bubble Syndrome. He said at a news conference that their goal was to develop a safe and effective therapy for SCID-X1 patients and their families, which is now in the clinical stage.

In the study, Trowbridge and his team used a vector derived from retroviruses, while retroviruses are ideal for gene therapy because they could insert their genes into the maternal genome and are less likely to activate nearby genes that may cause cancer.

The researchers found that after modifying the retrovirus-stem cell interaction method, the fusion degree of it with the surrounding genes was much better than that before the modification. They are convinced that the results of this study will help to achieve more effective gene therapies and they are looking forward to clinical trials within 5 years. Flarebio offer good-quality recombinant proteins like recombinant LARGE at good prices.

2016年11月4日星期五

A new drug to treat Alzheimer's disease has been developed

Alzheimer's disease has proved promising in a new experimental treatment program, which has no harmful side effects, US researchers reported on Wednesday. The study, published in the journal Science Translational Medicine, based on a small sample of 32 people, led to two broader clinical trials and is currently being studied with more than 3,000 participants. This treatment uses a compound known as verubecestat and was developed by American Pharmaceuticals using recombinant rat proteins. It reduces the level of protein called beta-amyloid by blocking the BACE1 enzyme.

In people with Alzheimer’s disease, protein aggregates form plaques that damage the brain, affecting people & apos; s cognitive abilities, especially memory. The enzyme plays a key role in the production of proteins. 32 patients who participated in the first clinical trial were diagnosed with mild to moderate Alzheimer's disease. Pharmaceutical laboratories are working to develop compounds that prevent or even reverse these plaque formations. The products used to neutralize BACEI enzymes so far have very deleterious side effects, such as liver damage or further neurodegeneration. But, says Matthew Kennedy, Ph.D., of the Merck Research Laboratory in northeastern New Jersey, Verubecestat does not. The researchers found that one or two doses of verubecestat compound sufficient to reduce protein levels without causing side effects.

Two phase III trials are currently underway and will be completed in July 2017 to evaluate the efficacy of verubecestat. If the results are good, the compound can be made into pills within two to three years. According to the forecast, in the United States the baby boomer generation (birth peak) more than 80 years of age, by 2050 suffering from Alzheimer's disease may be more than 28 million people. The World Health Organization says there are 36 million people in the world suffering from some form of dementia, most of them suffering from Alzheimer's disease.

If no effective treatment is available in the next few years, the figure is expected to double by 2030 to over 65.7 million and double again by 2050 if without effective treatment. Flarebio provides good-quality recombinant proteins such as recombinant LARGE at great prices.

2016年8月9日星期二

Protein in hake's eyes becomes new hope for people with corneal blindness

Corneal blindness is a visual impairment which affects about 10 million people in the worldwide. It occurs from the cornea becoming clouded, scarred or any other infection that ultimately affects the transparency of cornea, finally making a person blind. It includes a range of eye diseases, injuries or infections that damage the corneal tissues and lead to permanent blindness. Due to shortage of cornea donation, only 100,000 can receive transplantation each year. Now researchers have new findings in research using recombinant human proteins.

A recent study at the University of Auckland in New Zealand found that they can make use of a kind of protein in the eyes of hake to make alternatives of human cornea. The study is expected to solve the shortage of donated corneas.

Researchers from Auckland University said they can get rich protein from the eyes of hake and use them to create biological materials for "corneal tissue engineering" of human beings, namely manufacturing cornea alternatives.

Medical director and leading ophthalmologist from Focus London clinic Alam said, "This news brings new hope for thousands of people who are at the risk of blindness. In a recent trial in UK, doctors first used IOL (intraocular lens) to conduct transplantation. This is really encouraging news. However, the synthesis technology is still in its infancy, and the operation is expected to begin in 2017. If the eye crystals of the fish prove to be effective, it can change the fate of thousands of people in this country and around the world."

Biological Sciences researchers from University of Auckland said that the possibility of such transplant having rejection is very small. Flarebio Biotech LLC offers good-quality recombinant proteins including recombinant LARGE at good prices.